3D-printed ulcerative colitis treatment receives FDA clearance to start clinical trials

Nanjing, China-based Triastek, a pharmaceutical company, has received FDA investigational new drug clearance to begin clinical studies on its 3D-printed medicine, T21, designed to treat ulcerative colitis. 

T21 targets the colon segment of the GI tract. It is a delayed-release, colon-targeted oral tablet made possible through 3D printing and radio-imaging. 

Triastek has already received clearance for two additional 3D-printed medications. 

"We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients," Senping Cheng, MD, founder and CEO of Triastek, said in a Nov. 21 press release. "Delaying drug release and delivering oral dosage forms to the colon is challenging, so T21 offers a promising new option for patients by providing site-specific drug delivery and localized drug effect, mitigating potential side effects from systemic exposure. We look forward to advancing this treatment into the clinic and appreciate the FDA's support." 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast